TET1 and acute myeloid leukemia: The family of methylcytosine dioxygenases known as the ten-eleven translocation (TET) proteins, which includes TET1/2/3, converts 5 methylcytosine to 5-hydroxymethylcytosine (5hmC), resulting in active or passive DNA demethylation.[42] Due to its major oncogenic role in the pathogenesis of different AML subtypes, TET1 is a potential therapeutic target for the treatment of the disease.[43–46] According to a study by Li et al, HHT has powerful anti-AML effects both in vitro and in vivo.